M.D. Anderson Cancer Center
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Primary Objectives: To determine whether, in patients with oligometastatic pancreatic ductal adenocarcinoma, MDT to all sites of disease confers a benefit in PFS compared to systemic therapy alone. Secondary Objectives: Key secondary objective: To determine whether, in patients with oligometastatic pancreatic ductal adenocarcinoma, MDT to all sites of disease confers a benefit in OS compared to systemic therapy alone. To assess safety/tolerability of MDT in patients with oligometastatic PDAC. To assess time to new lesion formation between treatment arms. To assess time to next-line syste…
Inclusion Criteria: Age 18 Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. Histologic / cytologic confirmation of pancreatic ductal adenocarcinoma may come from the primary tumor (i.e., via FNA at initial diagnosis). Histological/pathologic confirmation of distant metastatic disease is not required if clinical and radiographic consensus is that the patient has distant metastatic disease. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 Candidate for MDT (including radiation therapy, surgical resection, ablation, and embolization) to all sites of…
Participants will receive treatment through radiation therapy
Arctuva estimate
Verify or correct the compensation shown for this listing.